Table 3.

Patients' characteristics according to the TGF‐β1 rs1800470, IFN‐γ rs2430561, TNF‐α rs361525, rs1800629, rs1800750, IL‐10 rs1800896, rs1800872, IL‐6 rs1800795 genotypes

	TGF‐β1 rs1800470			IFN‐γ rs2430561			TNF‐α rs361525				TNF‐α rs1800629			TNF‐α rs1800750				IL‐6 rs1800795			IL‐10 rs1800872			IL‐10 rs1800896
	GG	GA + AA	P‐value	TT	TA + AA	P‐value	GG	GA + AA	P‐value		GG	GA + AA	P‐value	GG	GA + AA		P‐value	CC	CG + GG	P‐value	GG	GT + TT	P‐value	TT	TC + CC	P‐value
Age groups
19‐40 y	3	49	.208	12	40	.369	47	5	.199	35		17	.821	50	2	.438		9	43	.623	21	31	.101	18	34	.108
41‐60 y	3	46		23	56		72	7		53		26		76	3			9	70		47	32		19	60
61‐90 y	10	85		19	76		92	3		60		35		94	1			14	81		49	46		37	58
Gender
Female	12	101	.038	30	83	.349	106	7	.789	76		37	.576	109	4	.683		17	96	.849	57	56	.690	33	80	.257
Male	4	109		24	89		105	8		72		41		111	2			15	98		60	53		41	72
WBC (cells/mm3)
<50 000	13	170	.977	41	142	.279	172	11	.453	113		72	.015	180	3	.085		25	158	.658	93	90	.555	61	122	.697
≥50 000	3	40		13	10		39	4		35		8		40	3			7	36		24	19		13	30
PLT (cells/mm3)
<40 000	9	110	.765	28	91	.892	108	11	.097	78		41	.984	114	5	.216		16	103	.745	62	57	.916	39	80	.992
≥40 000	7	100		26	81		103	4		70		37		106	1			16	91		55	52		35	72
Hgb (g/dL)
<10	13	153	.646	39	127	.815	153	13	.23	114		52	.094	161	5	1.00		25	141	.518	89	77	.356	53	113	.664
≥10	3	57		15	45		58	2		34		26		59	1			7	53		28	32		21	39
LDH level (IU/L)
<600	6	90	.676	20	76	.354	92	4	.20	53		43	.005	95	1	.244		10	86	.165	47	49	.467	30	66	.681
≥600	10	120		34	96		119	11		95		35		125	5			22	108		70	60		44	86
Blasts (in bone marrow, %)
<70	12	126	.236	29	109	.204	129	9	.930	89		49	.694	134	4	1.00		19	119	.833	73	65	.671	39	99	.072
≥70	4	84		25	63		82	6		59		29		86	2			13	75		44	44		35	53
AML subtype
de novo	13	169	.75	44	138	.75	168	14	.483	123		59	.071	176	6	.636		28	154	.03	93	89	.897	63	199	.517
sAML	3	37		10	30		39	1		21		19		40	0			2	38		22	18		10	30
tAML	0	4		0	4		4	0		4		0		4	0			2	2		2	2		1	3
Cytogenetic risk
Low‐risk	1	23	.153	7	17	.649	22	2	.121	10		14	.083	24	0	.184		5	19	.441	12	12	.409	7	17	.007
Intermediate	13	110		32	91		117	6		84		39		121	2			17	106		59	64		43	80
High‐risk	1	56		11	46		54	3		39		18		55	2			9	48		35	22		11	46
NA	1	21		4	18		18	4		15		7		20	2			1	21		11	11		13	9
ECOG status
≤1	4	35	.153	10	29	.778	36	3	.728	20		19	.044	37	2	.277		3	36	.203	19	20	.675	13	26	.931
≥2	12	175		44	143		175	12		128		59		183	4			29	158		98	89		61	126

Abbreviations: sAML, secondary AML; tAML, therapy related AML; NA, not available.

Bold values denoted statistically significant results (P < 0.05).